Skip to content
  • About
    • CEO Comment
    • Story of Nanologica
    • Management team
    • Board of Directors
    • Career
    • Privacy policy
  • Chromatography
    • NLAB Saga® for Preparative Chromatography
    • SVEA® HPLC Columns
    • Catalogues / Brochures
    • Applications
    • Technical Support
  • Drug Development
    • Drug delivery platform
    • Publications
  • Investor relations (EN)
    • Press releases
    • Financial reports
    • Presentations
    • Calendar
    • Corporate Governance
    • The Share
    • Subscribe
  • Investor relations (SE)
    • Pressmeddelanden
    • Finansiella rapporter
    • Presentationer
    • Kalender
    • Bolagsstyrning
    • Aktien
    • Prenumerera
  • Latest news
  • Contact
Menu
  • About
    • CEO Comment
    • Story of Nanologica
    • Management team
    • Board of Directors
    • Career
    • Privacy policy
  • Chromatography
    • NLAB Saga® for Preparative Chromatography
    • SVEA® HPLC Columns
    • Catalogues / Brochures
    • Applications
    • Technical Support
  • Drug Development
    • Drug delivery platform
    • Publications
  • Investor relations (EN)
    • Press releases
    • Financial reports
    • Presentations
    • Calendar
    • Corporate Governance
    • The Share
    • Subscribe
  • Investor relations (SE)
    • Pressmeddelanden
    • Finansiella rapporter
    • Presentationer
    • Kalender
    • Bolagsstyrning
    • Aktien
    • Prenumerera
  • Latest news
  • Contact

Bolagsstyrningsrapporter

Read more:

  • Pressmeddelanden
  • Finansiella rapporter
  • Presentationer
  • Kalender
  • Bolagsstyrning
    • Bolagsstyrningsrapporter
    • Bolagsordning
    • Stämmor
    • Valberedning
    • Styrelse
    • Styrelsens arbete
    • Ledningsgrupp
    • Ersättning
    • Incitamentsprogram
    • Revisorer
    • Visselblåsning
  • Aktien
    • Analytiker och analyser
    • Ägarstruktur
    • Aktiekapitalets utveckling
    • Notering på Nasdaq Stockholm
    • Företrädesemission 2022
    • Prenumerera
  • Prenumerera
  • Pressmeddelanden
  • Finansiella rapporter
  • Presentationer
  • Kalender
  • Bolagsstyrning
    • Bolagsstyrningsrapporter
    • Bolagsordning
    • Stämmor
    • Valberedning
    • Styrelse
    • Styrelsens arbete
    • Ledningsgrupp
    • Ersättning
    • Incitamentsprogram
    • Revisorer
    • Visselblåsning
  • Aktien
    • Analytiker och analyser
    • Ägarstruktur
    • Aktiekapitalets utveckling
    • Notering på Nasdaq Stockholm
    • Företrädesemission 2022
    • Prenumerera
  • Prenumerera

Bolagsstyrningsrapporter och revisorsyttranden

2023

Revisorns granskningsrapport Q3 2023

 

2022

Bolagsstyrningsrapport 2022 Nanologica AB (publ)

Revisorns yttrande Bolagsstyrningsrapport 2022

Revisionsberättelse 2022 Nanologica AB (publ)

Revisorns granskningsrapport Q3 2022

 

2021

Bolagsstyrningsrapport 2021 Nanologica AB (publ)

Revisionsberättelse 2021 Nanologica AB (publ)

Revisorns granskningsrapport Q3 2021

 

2020

Bolagsstyrningsrapport 2020

Revisionsberättelse 2020

Nanologica AB (publ)
Forskargatan 20 G
SE-151 36 Södertälje
Sweden

Email: info@nanologica.com
Tel: +46 (0)8 410 749 49

Subscribe

To subscribe to our press releases and financial reports, please enter your e-mail address. Tick the box to approve the subscription and accept our privacy policy:

About us

Nanologica is a Swedish life science tools company that provides input goods to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

© Nanologica 2023
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT